Results 181 to 190 of about 10,503 (191)
Some of the next articles are maybe not open access.

Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis

Expert Opinion on Biological Therapy, 2019
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis characterized by asthma, hypereosinophilia, and progressive multiorgan involvement. Although not fully elucidated, advancement in our understanding of the pathophysiology of EGPA has led to the development of multiple new ...
Jason Kihyuk Lee   +2 more
openaire   +3 more sources

Mepolizumab-responsive Kimura disease

The Journal of Allergy and Clinical Immunology: In Practice, 2021
Manao Kinoshita   +4 more
openaire   +3 more sources

Mepolizumab-based therapy in asthma

Current Opinion in Allergy & Clinical Immunology, 2015
There is considerable evidence that implicates eosinophils as important effector cells in the inflammation characteristic of eosinophilic asthma. IL-5 is central to eosinophil maturation and release from the bone marrow, their subsequent accumulation, activation and persistence in the tissues.
openaire   +3 more sources

Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis

Drugs of Today, 2018
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare but potentially life-threatening antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis which affects, to varying degrees, the lungs, paranasal sinuses, heart, kidneys, skin and peripheral nervous system. It is strongly associated with asthma. Peripheral eosinophilia is a defining
Claire McBrien, Andrew Menzies-Gow
openaire   +3 more sources

Mepolizumab for the treatment of severe eosinophilic asthma

American Journal of Health-System Pharmacy, 2017
Published data on the pharmacology, pharmacokinetics and pharmacodynamics, and clinical efficacy and safety of the interleukin-5 antagonist mepolizumab are reviewed.Asthma of the eosinophilic phenotype is characterized by persistent eosinophilic airway inflammation promoted primarily by T-helper type 2 cytokines, the key regulator of eosinophils ...
Allen L. Wolford   +3 more
openaire   +2 more sources

Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis

New England Journal of Medicine
Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis characterized by eosinophilic inflammation. Benralizumab, a monoclonal antibody against the interleukin-5α receptor expressed on eosinophils, may be an option for treating EGPA.We conducted a multicenter, double-blind, phase 3, randomized, active-controlled noninferiority trial to ...
Wechsler, Michael E   +18 more
openaire   +4 more sources

Hypereosinophilic Syndrome and Mepolizumab

New England Journal of Medicine, 2008
Robert M, Boucher   +2 more
openaire   +4 more sources

Mepolizumab for chronic rhinosinusitis with nasal polyps

The Lancet Respiratory Medicine, 2021
Philippe Gevaert, Guy Brusselle
openaire   +3 more sources

Mepolizumab use

Annals of Allergy, Asthma & Immunology, 2018
Mariel R. Benjamin   +2 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy